BioNTech与OncoC4公布gotistobart更新数据：经治鳞状NSCLC中位OS近乎翻倍
BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
BioNTech与OncoC4公布gotistobart更新数据，在既往接受过治疗的鳞状非小细胞肺癌患者中，中位总生存期较标准化疗近乎翻倍。具体数值、样本量与统计细节以原文为准。
可跟踪gotistobart在经治鳞状NSCLC的OS数据成熟度及注册推进节奏。
- Home
- Media
News & Media
Explore the latest news from BioNTech, including press releases, media updates, and further press material for download.
Oncology
09.14.2026
BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
Latest News
Annual report 2025
In 2025, BioNTech has gained momentum in executing its strategy and shaping the future of medicine. Building on the foundation laid in recent years, we have accelerated our evolution with the aim of becoming a multi-product company. Access our 2025 annual report for insights into achievements, pipeline updates and a summary of our financial results.
For healthcare professionals
Our innovative research and development programs are focused on delivering transformative treatments for patients with cancer. We are committed to working with healthcare professionals to improve patient outcomes.
Stay up to date
You want to receive the latest information about our company by e-mail? Sign up to our mailing list.
补充资料（1 节）投资者与媒体联系
投资者与媒体联系
For investors
We are dedicated to driving shareholder value through strategic investments in innovative oncology therapies. Our leadership is committed to transparency and delivering long-term growth.
来源：BioNTech · investors.biontech.de